Magnifying NBI for Occult NPC (NCT04593186) | Clinical Trial Compass
UnknownNot Applicable
Magnifying NBI for Occult NPC
Hong Kong246 participantsStarted 2021-04-15
Plain-language summary
Diagnosis of nasopharyngeal carcinoma (NPC) is currently made by trans-nasal endoscopy and biopsy. The small caliber endoscope provides only a limited view of the nasopharynx and may not be able to provide a thorough assessment of the nasopharynx. The investigators have developed a novel endoscopic approach to access the nasopharynx by using a trans-oral high definition endoscope with magnification and image enhancement function. In this cohort study, we aim to investigate the efficacy of diagnosing NPC by applying the novel technique in a high risk patient group with elevated plasma EBV DNA but with negative screening with conventional trans-nasal endoscopy.
Who can participate
Age range18 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male, age ≥ 18 years old
✓. Positive result on plasma EBV-DNA analysis
✓. No cancer identified on conventional investigations including nasoendoscopy and MRI
Exclusion criteria
✕. History of nasopharyngeal, oropharyngeal cancer
✕. Patients on anticoagulation (Including warfarin and other direct oral anti-coagulants)
✕. Bleeding tendency (International Normalized Ratio (INR) \> 1.5 or Platelet \< 50 x109/L)
✕. Trismus, unable to pass oral endoscope
✕. Allergic to local anaesthetic agents (Lignocaine)
✕. Failure of vital organ (heart, lungs, liver, or kidneys) function
✕. Other conditions deemed unsuitable for endoscopy